Appropriate Use Criteria For Amyloid PET

Publication Date: January 1, 2013
Last Updated: March 14, 2022

Appropriate Indications

Patients with persistent or progressive unexplained mild cognitive impairment (MCI)
6731
Patients satisfying core clinical criteria for possible Alzheimer’s disease (AD) (i.e., atypical clinical course or etiologically mixed presentation)
6731
Patients with atypically young-onset dementia
6731

Not Appropriate Indications

Patients with core clinical criteria for probable AD with typical age of onset
6731
To determine dementia severity
6731
Based solely on a positive family history of dementia or presence of APOE ε4
6731
Patients with a cognitive complaint that is unconfirmed on clinical examination
6731
In lieu of genotyping for suspected autosomal mutation carriers
6731
The clinical use of amyloid positron emission tomography (PET) in asymptomatic individuals
6731
Nonmedical usage -- e.g., legal-, disability-, and employment-related matters
6731

Recommendation Grading

Overview

Title

Appropriate Use Criteria For Amyloid PET

Authoring Organizations

Publication Month/Year

January 1, 2013

Last Updated Month/Year

January 8, 2024

Supplemental Implementation Tools

Document Type

Consensus

External Publication Status

Published

Country of Publication

US

Document Objectives

To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evi- dence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used.

Inclusion Criteria

Female, Male, Adult, Older adult

Health Care Settings

Ambulatory, Outpatient

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Assessment and screening, Diagnosis, Management

Diseases/Conditions (MeSH)

D000066492 - Cognitive Aging, D003072 - Cognition Disorders

Keywords

dementia, mild cognitive impairment, Alzheimer disease, amyloidosis

Source Citation

Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9(1):e‐16. doi:10.1016/j.jalz.2013.01.002